Search Results

Achilles Therapeutics plc announced its financial results for the first quarter ended March 31, 2024, and recent business highlights.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens.

Achilles Therapeutics plc announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Achilles Therapeutics plc disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference.

Achilles Therapeutics plc today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance, and proposes a path forward.